Memantine STADA 10 mg filmomhulde tabletten

How does Memantine STADA work

Memantine STADA belongs to a group of medicines known as anti-dementia medicines.

Memory loss in Alzheimer’s disease is due to a disturbance of message signals in the brain. The brain contains so-called N-methyl-D-aspartate (NMDA)-receptors that are involved in transmitting nerve signals important in learning and memory. Memantine STADA belongs to a group of medicines called NMDA- receptor antagonists. Memantine STADA acts on these NMDA-receptors improving the transmission of nerve signals and the memory.

What is Memantine STADA used for

Memantine STADA is used for the treatment of patients with moderate to severe Alzheimer’s disease.

Do not take Memantine STADA

• if you are allergic to memantine hydrochloride or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor or pharmacist before taking Memantine STADA.

• if you have a history of epileptic seizures
• if you have recently experienced a myocardial infarction (heart attack), or if you are suffering from congestive heart failure or from an uncontrolled hypertension (high blood pressure).

In these situations the treatment should be carefully supervised, and the clinical benefit of Memantine STADA reassessed by your doctor on a regular basis.

Ver. 03

If you suffer from renal impairment (kidney problems), your doctor should closely monitor your kidney function and if necessary adapt the memantine doses accordingly.

The use of medicinal products called amantadine (for the treatment of Parkinson’s disease), ketamine (a substance generally used as an anaesthetic), dextromethorphan (generally used to treat cough) and other NMDA-antagonists at the same time should be avoided.

Children and adolescent

Memantine STADA is not recommended for children and adolescents under the age of 18 years.

Other medicines and Memantine STADA

Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines.

In particular, Memantine STADA may change the effects of the following medicines and their dose may need to be adjusted by your doctor:

amantadine, ketamine, dextromethorphan dantrolene, baclofen

cimetidine, ranitidine, procainamide, quinidine, quinine, nicotine hydrochlorothiazide (or any combination with hydrochlorothiazide)

anticholinergics (substances generally used to treat movement disorders or intestinal cramps) anticonvulsants (substances used to prevent and relieve seizures)

barbiturates (substances generally used to induce sleep) dopaminergic agonists (substances such as L-dopa, bromocriptine) neuroleptics (substances used in the treatment of mental disorders) oral anticoagulants

If you go into hospital, let your doctor know that you are taking Memantine STADA.

Memantine STADA with food and drink

You should inform your doctor if you have recently changed or intend to change your diet substantially (e.g. from normal diet to strict vegetarian diet) or if you are suffering from states of renal tubulary acidosis (RTA, an excess of acid-forming substances in the blood due to renal dysfunction (poor kidney function)) or severe infections of the urinary tract (structure that carries urine), as your doctor may need to adjust the dose of your medicine.

Pregnancy and breast-feeding

Ask your doctor or pharmacist for advice before taking any medicine.

Tell your doctor if you are pregnant or planning to become pregnant. The use of memantine in pregnant women is not recommended.

Women taking Memantine STADA should not breast-feed.

Driving and using machines

Your doctor will tell you whether your illness allows you to drive and to use machines safely.

Also, Memantine STADA may change your reactivity, making driving or operating machinery inappropriate.

Always take this medicine exactly as your doctor or pharmacist has told you. You should check with your doctor or pharmacist if you are not sure.

Dosage

The recommended dose of Memantine STADA for adults and elderly patients is 20 mg once a day. In order to reduce the risk of side effects this dose is achieved gradually by the following daily treatment scheme:

Ver. 03

Week 1	half a 10 mg tablet
Week 2	one 10 mg tablet
Week 3	one and a half 10 mg tablets
Week 4 and beyond	two 10 mg tablets once a day

The usual starting dose is half a tablet once a day (1x 5 mg) for the first week. This is increased to one tablet once a day (1x 10 mg) in the second week and to 1 and a half tablets once a day in the third week. From the fourth week on, the usual dose is 2 tablets once a day (1x 20 mg).

Dosage in patients with impaired kidney function

If you have impaired kidney function, your doctor will decide upon a dose that suits your condition. In this case, monitoring of your kidney function should be performed by your doctor at specified intervals.

Administration

Memantine STADA should be administered orally once a day. To benefit from your medicine you should take it regularly every day at the same time of the day. The tablets should be swallowed with some water.

The tablets can be taken with or without food.

Duration of treatment

Continue to take Memantine STADA as long as it is of benefit to you. Your doctor should assess your treatment on a regular basis.

If you take more Memantine STADA than you should

• In general, taking too much Memantine STADA should not result in any harm to you. You may experience increased symptoms as described in section 4. “Possible side effects”.
• If you take a large overdose of Memantine STADA, contact your doctor or get medical advice, as you may need medical attention.

If you forget to take Memantine STADA

• If you find you have forgotten to take your dose of Memantine STADA, wait and take your next dose at the usual time.
• Do not take a double dose to make up for a forgotten dose.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

Like all medicines, this medicine can cause side effects, although not everybody gets them. In general, the observed side effects are mild to moderate.

Common (may affect up to 1 in 10 people):

• Headache, sleepiness, constipation, elevated liver function tests, dizziness, balance disorders, shortness of breath, high blood pressure and drug hypersensitivity

Uncommon (may affect up to 1 in 100 people):

• Tiredness, fungal infections, confusion, hallucinations, vomiting, abnormal gait, heart failure and venous blood clotting (thrombosis/thromboembolism)

Very Rare (may affect up to 1 in 10,000 people):

 Seizures

Not known (frequency cannot be estimated from the available data):

 Inflammation of the pancreas, inflammation of the liver (hepatitis) and psychotic reactions

Ver. 03

Alzheimer’s disease has been associated with depression, suicidal ideation and suicide. These events have been reported in patients treated with memantine.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and the blister after EXP. The expiry date refers to the last day of that month.

This medicinal product does not require any special storage conditions.

Do not throw away any medicines via wastewater . Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

What Memantine STADA contains

The active substance is memantine hydrochloride. Each film-coated tablet contains 10 mg memantine hydrochloride equivalent to 8.31 mg memantine.

The other ingredients are microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica and magnesium stearate, all in the tablet core; and polyvinyl alcohol, titanium dioxide (E171), macrogol (3350) and talc, all in the tablet coating.

What Memantine STADA looks like and contents of the pack

Memantine STADA film-coated tablets are presented as white, slim through the middle, biconvex, 10 mm – 5,6 mm, film-coated tablet with breaking lines on both sides and engraving ‘1 0’ on one side.

The tablet can be divided into equal doses.

for NL/H/2726/001/DC

Blister packs containing either 10, 14, 15 or 20 tablets per blister (PVC/PE/PVDC and Aluminium). Memantine STADA film-coated tablets are presented in pack sizes of 28, 30, 50, 56 or 100 film-coated tablets.

for NL/H/2727/001/DC

Blister packs containing either 7, 10, 14, 15 or 20 tablets per blister (PVC/PE/PVDC and Aluminium). Memantine STADA film-coated tablets are presented in pack sizes of 7, 14, 28, 30, 42, 50, 56, 60, 98, 110, 112, 168 or 180 film-coated tablets.

for NL/H/2728/001/DC

Blister packs containing either 7, 10, 14 or 20 tablets per blister (PVC/PE/PVDC and Aluminium). Memantine STADA film-coated tablets are presented in pack sizes of 7, 14, 42, 50, 60 or 98 film-coated tablets.

Not all pack sizes may be marketed.

Houder van de vergunning voor het in de handel brengen en fabrikant

Ver. 03

STADA Arzneimittel AG

Stadastr. 2-18,

61118 Bad Vilbel

Germany

Fabrikant

Cemelog-BRS Ltd.

Vasút u. 13 (Pharma Park) 2040 Budaörs

Hongarije

In het register ingeschreven onder:

RVG 112205

Deze bijsluiter is voor het laatst goedgekeurd in november 2013.

Ver. 03